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Abstract and Keywords  
There is a growing recognition of the impact of environmental toxins on the epigenetic 
regulation of gene expression, including the genes that play a critical role in neural development, 
neural function and neurodegeneration.  We have shown previously that exposure to the heavy 
metal lead (Pb) in early life results in a latent over-expression of AD-related proteins in rodents 
and primates.  The present study provides evidence that early postnatal exposure to Pb also alters 
the expression of select miRNA.  Mice were exposed to 0.2% Pb acetate from Postnatal Day 1 
(PND 1, first 24 hours after birth) to PND 20 via their mother’s milk, brain tissue was harvested 
at PND 20, 180, or 700 and miRNA were isolated and quantified by qPCR.   This exposure 
produced a transient increase (relative to control) in the expression of miR-106b (binds to AβPP 
mRNA), miR-29b (targets the mRNA for the transcription factor SP1) and two miRNAs (miR-
29b and miR-132) that have the ability to inhibit translation of proteins involved in promoter 
methylation.  The expression of miR-106b decreased over time in the Pb-exposed animals and 
was significantly less than the levels exhibited by the control animals at PND700.  The level of 
miR-124, which binds to SP1 mRNA, was also reduced (relative to controls) at PND700.   In 
summary, we show that exposure to the heavy metal Pb in early life has a significant impact on 
the short- and long-term expression of miRNA that target epigenetic mediators and neurotoxic 
proteins.   
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Introduction  
Alzheimer’s disease (AD) is the most common neurodegenerative disease and the major 
cause of dementia.  A very small proportion (less than 5%) of individuals with AD develops the 
disease before age 65, and is considered to have Early Onset Alzheimer’s Disease. The 
overwhelming majority of AD cases are sporadic, or late onset AD (LOAD). To date, no 
mutation, other than a risk associated with carrying certain susceptibility alleles (currently 
numbering approximately 24), has been linked to LOAD [1-5].  The failure to identify a clear 
genetic etiology for LOAD suggests the likelihood that environmental and/or epigenetic factors 
play an important role in initiating and influencing the cascade of events that leads to this form 
of AD [6]. 
There is a growing recognition of the impact of environmental factors such as heavy 
metals, diet, pesticides and stress on the epigenetic regulation of gene expression, including the 
genes that play a critical role in neural development, neural function and neurodegeneration [7, 
8].  One toxicant that has generated particular concern is the heavy metal lead (Pb), and our 
laboratory was in fact the first to provide evidence of a potential link between Pb and AD when it 
demonstrated that exposure to Pb in early life resulted in latent over-expression of AD-related 
proteins in rodents [9]. We found subsequently that developmental exposure to Pb produced a 
transient increase in the binding of the transcription factor specificity protein 1 (SP1) to DNA, 
together with a brief increase in the expression of the mRNA for amyloid-β precursor protein 
(AβPP) and microtubule-associated protein tau (MAPT) [9-12].  This very transient increase was 
followed by a delayed increase in SP1 binding together with a delayed overexpression of AβPP 
mRNA, AβPP, amyloid-β (Aβ), Mapt mRNA and hyperphosphorylated tau in later life [9, 12, 
13].  Importantly, these changes do not occur when animals are exposed to Pb in old age.  The 
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results we obtained using our rodent model of environmental Pb exposure have been verified and 
expanded using tissue obtained from primates that were exposed to Pb during infancy. Tissue 
obtained from the cerebral cortex of adult (23 years) monkeys exposed to Pb between PND 0-
400 exhibited pathologic neurodegeneration, an overexpression of SP1 mRNA, SP1, AβPP, Aβ, 
MAPT mRNA and tau and a decrease in the expression of the methylation-related proteins DNA 
(Cytosine-5-)-Methyltransferase (DNMT)1, DMNT3a and Methyl CpG Binding Protein 2 
(MECP2) [14-16].   
Our data regarding Pb-induced changes in SP1, DNMT1, DMNT3a and MeCP2 provide 
support for the hypothesis that the delayed overexpression of AD-related proteins involves 
changes to the epigenome.  The challenge, therefore, is to identify a mechanism that can explain 
the delayed emergence of epigenetic modifications that are “triggered” by an environmental 
stimulus in early life.  We suggest that the cancer literature offers some potentially important 
insights.  Work conducted by a number of laboratories has revealed an intriguing interaction 
between transcription factors, DNMTs and microRNA (miRNA) during oncogenesis [17-22].  
The interactions between SP1, the DNMTs and miRNA in oncogenesis provide a framework for 
developing and testing postulates regarding the roles that epigenetic mediators and transcription 
factors play in the development of LOAD.  Our global hypothesis is that early-life exposure to 
Pb is a toxic trigger that initiates a cascade of epigenetic changes, beginning with the transient 
activation of the transcription factor SP1 and its brief activation of select subsets of miRNA.  We 
propose that subsequent accumulating stochastic changes alter miRNA expression and produce a 
second increase in SP1 expression in later life, resulting in an increase in the transcription of 
toxic AD-related proteins. 
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The present study begins the process of testing our global hypothesis by examining the 
expression of specific miRNA in animals that were exposed to Pb in early life. Recent reviews 
have identified a small number of miRNA that consistently exhibit increased or decreased 
expression in AD patients [23, 24].  We used the miRTarBase database 
(http://mirtarbase.mbc.nctu.edu.tw/)[25] to select six of these miRNA that target the mRNA for 
AβPP, MAPT, DNMT1,3a or 3b, SP1 and/or MECP2 and quantified their expression in animals 
that were exposed to Pb to determine whether 1) their expression is altered by Pb exposure and 
2) changes in miRNA levels are consistent with their potential role in the delayed overexpression 
of neurotoxic AD-related proteins.  
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Materials and methods  
Animal exposure  
All protocols were conducted in accordance with approval granted by the Institutional 
Animal Care and Use Committee at the University of Rhode Island (URI).  Timed pregnant 
C57BL/6J strain mice were purchased from Jackson Laboratories (ME, USA) and housed at the 
Animal Care Facility at URI.  Male pups from different dams were pooled and allocated 
randomly to control and Pb-exposed (PbE) groups.  The mothers (N = 9) of the animals in the 
control group consumed tap water, whereas the mothers (N = 9) of animals in the PbE group 
drank tap water containing 0.2% Pb acetate from Postnatal Day 1 (PND 1, first 24 hours after 
birth) to PND 20.  Three mice from the control group and three mice from the PbE group were 
euthanized and their brains harvested at PND 20, 180, or 700 and their hippocampi were stored 
at -80⁰C until use (total 9 control and 9 PbE animals).   Tissue from these animals was used for 
the present study as well as our previous investigations that determined the effect of early-life Pb 
exposure on the expression of AβPP mRNA, AβPP, Aβ, Mapt mRNA and MAPT [12, 26]. 
Total RNA isolation and miRNA real-time polymerase chain reaction  
Total RNA was extracted from control and PbE brain tissue according to the TRIzol 
method (Invitrogen, CA) as per manufacturer protocol. The quality of extracted RNA was 
verified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, NY). 
Complementary DNA (cDNA) of miRNA was synthesized from 1 µg of total RNA using the 
NCode™ VILO™ miRNA cDNA Synthesis Kit (Invitrogen, CA) as per manufacturer protocol. 
The qPCR analyses of synthesized cDNA were performed using SYBR Green qRT-PCR assays 
(20 µl reactions in replicates, using AβAppropriate amount of cDNA template, 10 µl SYBR 
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Green master mix, 500 nM final concentration of forward and reverse primers, and deionized 
water) with amplification performed in the ViiA 7 Real-Time PCR system (Applied Biosystem, 
CA).  The expression was reported relative to sno202 miRNA with the 2-ΔCt method. 
Statistical analysis 
Traditionally, real-time quantitative RT-PCR (qPCR) cycles-to-threshold (CT) values are 
converted to normalized “fold” differences between groups before being subjected to statistical 
analysis. A difficulty with this method is that CT values are generally Gaussian, whereas fold 
differences imply proportional effects and variances that change with means. We employed a 
general linear model (GLM) analytic technique [27, 28] that allowed us to test an array of linear 
hypotheses accompanying our multi-factored design, including higher-order interactions.  All 
analyses were carried out with SAS version 9.4 (The SAS Institute, Cary, NC). Proc glimmix 
was used to construct general linear models of CT values directly, which mirrored the 
experimental design. The GLMs accounted for the repeated measures within mouse (multiple 
miRNAs) using correlated residual errors. This was necessary as the corollary of the within-
animal subtraction of the housekeeping gene CT for normalization. A compound symmetry 
variance-covariance structure was used to fit the model initially. This assumes homogenous 
variances of miRNA and a common covariance between pairs of miRNA within animal.   
Classical sandwich estimation was used to automatically adjust for differences in miRNA 
variance and changes in covariance between pairs of miRNA. The models were 3-way factorial 
models, with main effects for miRNA, treatment, and age, along with all 2-way and 3-way 
interactions included in the main model. Individual a priori specified hypothesis tests were 
carried out within the model as complex orthogonal comparisons, comparing groups while 
normalizing to the housekeeping gene (difference of the difference = ΔΔCT). Family-wise alpha 
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was maintained at 0.05 using the Holm test, though unadjusted p-values were also presented in 
some instances. The (geometric) mean and 95%CI of normalized concentrations of target 
miRNA (2-ΔCT) were used to illustrate how different conditions varied across time. 
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Results 
The expression of miR-106b (targets AβPP mRNA), miR-34c (MAPT mRNA), miR-124 
(SP1 mRNA), miR-29b (DNMT3a,b; Dnmt3a,b and SP1 mRNA), miR-148a (DNMT1 and 
Dnmt1 mRNA) and miR-132 (MECP2 and Mecp2 mRNA) was measured using qPCR at PND 
20, 180 and 700 in animals that were exposed to Pb (and their controls) from PND 1-20 via 
mothers’ milk.  
miR-106b 
Figure 1A illustrates the expression of miR-106b, a miRNA that has been shown to target 
the mRNA for the human AβPP gene [29].  The data demonstrate that the animals responded to 
Pb exposure with an increase in the production of miR-106b, but this increase was not 
maintained throughout the lifespan.  We found that the animals exposed to Pb had a 1.5-fold 
increase in the expression of miR-106b, relative to control, at PND20 (95% confidence interval 
1.1-2.1, p=0.02, adjusted p=0.28).  The expression of miR-106b decreased substantially in the 
Pb-exposed animals between PND20-180 and was 1.7-fold lower than levels seen in age-
matched control animals at PND700 (95% CL 2.2-1.1, p=0.0078, adjusted p=0.11).  There was 
no significant change over time in the expression of miR-106b in the animals that were not 
exposed to Pb.   
miR-34c 
 The expression of miR-34c, a miRNA that targets the mRNA for MAPT [30], is shown in 
Figure 1B.  We found that the expression of this miRNA remained relatively unchanged, across 
the lifespan, in the animals that had been exposed to Pb.  Interestingly, this contrasts with the 
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expression of miR-34c in normal animals, which exhibited a dramatic increase in miR-34c levels 
between PND20 and 180.  The difference between the two groups was most apparent at 
PND180, where the expression of miR-34c in the control animals was 1.6-fold greater than that 
seen in the Pb-exposed animals (95% CI 2.0-1.4, p<0.0001, adjusted p<0.0001).   
miR-124 
 Figure 1C illustrates the expression of miR-124, a miRNA that targets the mRNA for SP1 
[31].  The levels of miR-124 in the Pb-exposed animals remained relatively unchanged between 
PND20 and 180 and reflected the levels seen in control animals.  This profile changed 
dramatically, however, between PND180-700.  The expression of miR-124 in the animals 
exposed to Pb decreased dramatically in this interval, and at PND700 the level of miR-124 in the 
Pb-exposed animals was 2.0-fold less than the controls (95% CI 3.8-1.1, p=0.02, adjusted 
p=0.33).  There was no significant change over time in the expression of miR-124 in the animals 
that were not exposed to Pb.   
miR-29b 
 The expression of miR-29b, a miRNA that targets the mRNA for DNMT3 [32], Dnmt3 
[33] and SP1 [34-37] mRNA, is illustrated in Figure 1D.  The level of miR-29b in the animals 
exposed to Pb was 1.6-fold greater than the level exhibited by controls on PND20 (95% CI 1.4-
1.9, p<0.0001, adjusted p<0.0001).  Both groups exhibited a significant increase in the 
expression of this miRNA between PND20 and PND180, with the increase associated with the 
control group particularly striking.  The expression of miR-29b did not change for either group 
between PND180-700.    
miR-148a 
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 Figure 1E depicts the expression of miR-148a, which has documented targets on DNMT1 
[38] and Dnmt1 [39] mRNA. Comparisons at each of the three time points failed to identify any 
significant differences in the expression of miR-148a in Pb-exposed and control animals. 
miR-132 
 The expression of miR-132, which targets MECP2 [40] and Mecp2 [41] mRNA, is 
illustrated in Figure 1F.  We found that early life Pb exposure produced a dramatic increase 
(relative to normal) in the expression of this miRNA at PND20.   The level of miR-132 in the Pb-
exposed animals was 4.8-fold greater than the level associated with the control animals (95% CI 
2.4-9.7, p<0.0001, adjusted p=0.0004).  
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Discussion 
The present study demonstrates that exposure to the heavy metal Pb in early life has a 
significant impact on the expression of miRNA that target epigenetic mediators and neurotoxic 
proteins.  Brief developmental exposure to this toxicant produced an early postnatal increase 
(relative to control) in the expression of a miRNA (miR-106b) that has been shown to bind to the 
3’ untranslated region of AβPP mRNA, a miRNA (miR-29b) that targets SP1 and two miRNAs 
(miR-29b and miR-132) that have the ability to inhibit translation of proteins involved in 
promoter methylation.  The expression of miR-106b decreased over time in the Pb-exposed 
animals and was significantly less than the levels exhibited by the control animals at PND700.  
The level of miR-124, which binds to SP1 mRNA, was also reduced (relative to controls) at 
PND700.   
How might we understand the evolution and potential impact of these changes in miRNA 
expression?  In previous studies, using the same animals employed in the present investigation, 
we have demonstrated that developmental exposure to Pb produced a transient increase in the 
binding of SP1 to DNA, together with a brief increase in the expression of AβPP and Mapt 
mRNA [9-12].  This brief increase in AβPP and Mapt mRNA was followed by an extended 
“latent” period during which the levels of these mRNA were indistinguishable from normal.  As 
the animals approach PND700, however, there was a latent overexpression of AβPP mRNA, 
AβPP, Aβ, Mapt mRNA and hyperphosphorylated tau [9, 12, 13].  We propose that the Pb-
induced transient increase in SP1 binding to DNA allows the transcription factor to increase 
transcription of select miRNA, allowing them to participate in the normalization of AβPP, SP1 
and MAPT levels that lasts for many months in rodents and many years in primates [9, 11, 14, 
42-45]. Increased expression of miR-29b in the early postnatal period, for example, would 
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conceivably allow this miRNA to inhibit the production of SP1, while the early postnatal 
increase in miR-106b would inhibit the expression of AβPP.  Meanwhile, increased production 
of miR-29b and miR-132 would act to inhibit the translation of the methylation-related proteins.  
This decrease in the expression of the DNMTs and MECP2 would facilitate the continued 
expression of miR-106b and miR-29b if their expression is sensitive to promoter methylation.  
We predict that the miRNA that participate in the regulation of AD-related proteins are 
subject to accumulating stochastic changes similar to those associated with miRNA that play a 
role in oncogenesis [46-48].   We propose that the symptomatic period of LOAD is initiated by a 
reduction in the expression of some of the miRNA targeting SP1, AβPP, and MAPT mRNA, 
producing a decrease in post-transcriptional inhibition of SP1, AβPP and MAPT.  This would 
result in an increase in the expression of neurotoxic Aβ and tau.  Though the increased 
availability of SP1 and continued hypomethylation of the miR-106b and miR-124 promoters 
would seem to afford an opportunity to enhance transcription of these miRNA, we suggest that 
the loss-of-function changes to these miRNA will have greater influence. 
Conclusion 
We have shown that exposure to the heavy metal Pb in early life has a significant impact 
on the expression of miRNA that target epigenetic mediators and neurotoxic proteins.  Three of 
the six miRNA we studied exhibited an increase in expression in the period immediately 
following the Pb exposure and we suggest that these and similar miRNA may participate in the 
post-exposure normalization of gene expression that we have described previously. The 
expression of two miRNA decreased over time in the Pb-exposed animals and we predict that 
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these and related decreases in specific cerebral miRNA contribute to the over-expression of 
neurotoxic proteins in later life.  
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Table 1 
 
 
Target	   miRBase	  ID	   Primer	  sequence	  
miR-­‐
29b	  
MI0000143	   5’-­‐GCTGGTTTCATATGGTGGTTTA-­‐3’	  
miR-­‐
34c	  
MI0000403	   5’-­‐AGGCAGTGTAGTTAGCTGATTGC-­‐3’	  
miR-­‐
106b	  
MI0000407	   5’-­‐TAAAGTGCTGACAGTGCAGAT-­‐3’	  
miR-­‐
124	  
MI0000716	   5’-­‐CGTGTTCACAGCGGACCTTGAT-­‐3’	  
miR-­‐
132	  
MI0000158	   5’-­‐AACCGTGGCTTTCGATTGTTAC-­‐3’	  
miR-­‐
148	  
MI0000550	   5’-­‐AAAGTTCTGAGACACTCCGACT-­‐3’	  
sno-­‐202	  	   	   Forward:	  5’-­‐GCTGTACTGACTTGATGAAG-­‐3’	  
Reverse:	  5’-­‐CATCAGATGGAAAAGGGTTC-­‐3’	  
	  
Table	  1.	  miRNA	  and	  housekeeping	  gene	  primers	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Fig. 1 Expression of miRNA relative to sno202 in control animals (dotted line) and Pb-
exposed animals (PbE, solid line) at PND 20, 180 and 700. Results expressed as mean 
± 95% CI using the Holm post hoc test (p<0.05 considered significant compared to 
control, indicated by *), n=3 with measurements in triplicates.  
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